Thrombopoietin receptor agonist humanized VB22B single-chain diabody (hVB22B (scFv) 2 ) was found to be expressed as a mixture of two conformational isomers, a single-chain diabody form and a bivalent scFv form, which had different V H /V L (variable region of the heavy chain/light chain) association patterns. The single-chain diabody form showed significantly higher biological activity than the bivalent scFv form and, when incubated at elevated temperatures, exhibited novel isomerization to the inactive bivalent scFv form. Therefore, therapeutic development of hVB22B (scFv) 2 would require separation of the purified single-chain diabody form from the mixture of the two conformational isomers and also inhibition of isomerization into an inactive bivalent scFv form during storage. Novel V H /V L interface engineering in hVB22 (scFv) 2 , in which hydrogen bonding between H39 and L38 was substituted with electrostatic interaction to enhance the desired V H /V L association and inhibit the undesired V H /V L association, enabled selective expression of the desired conformational isomer without any reduction in biological activity or thermal stability. Moreover, V H /V L interface-engineered hVB22 (scFv) 2 was completely resistant to isomerization. Because the hydrogen bonding interaction between H39 and L38 and the surrounding residues are highly conserved in human antibody sequences, V H /V L interface engineering could be generally applied to various (scFv) 2 molecules for selective expression and inhibition of the isomerization of conformational isomers.
Introduction
Monoclonal antibodies have become important therapeutic options for the treatment of numerous diseases (Brekke and Sandlie, 2003; Maggon, 2007) . Most monoclonal antibodies currently on the market are IgG antibodies. Other therapeutic antibodies include antibody fragments such as Fab and single-chain Fv (scFv). Several Fab fragment antibodies have been developed, and several scFv fragments are currently under clinical development (Holliger et al., 2005) . scFv contains the complete antigen-binding site, in which the variable region of the heavy chain (V H ) is connected via a flexible linker to the variable region of the light chain (V L ), and can be expressed in a wide range of hosts, including mammals, bacteria and yeasts. scFv can be expressed as a monomer, dimer or multimer depending on the length of the linker between V H and V L (Desplancq et al., 1994; Hudson et al., 1999) . When scFv is expressed as a non-covalent dimer using a short linker, it is referred to as a diabody (Perisic et al., 1994) . On the other hand, two scFvs can be covalently connected by a third linker to generate a single-chain diabody ((scFv) 2 ) represented by the format VH1-linker-VL1-linker-VH2-linker-VL2 (Kontermann et al., 1999) . Because a diabody and (scFv) 2 each contain two antigen binding sites, both molecules have various applications, such as small tumor targeting moiety by bivalent binding to the tumor antigen (Kortt et al., 2001) , bispecific antibody format for targeting two different tumor antigens (Jimenez et al., 2005) and bispecific antibody format for recruiting effector cells to tumor cells (Baeuerle et al., 2009) .
Recently, Orita et al. (2005) reported that anti-Mpl IgG1 antibody converted into non-covalent diabody or (scFv) 2 had significantly enhanced thrombopoietin receptor agonist activity, demonstrating that conversion of IgG antibody into a non-covalent diabody or an (scFv) 2 molecule, having two antigen-binding sites spatially closer than IgG, would be a novel strategy for efficiently generating agonistic antibody. Likewise, tumor cell death-inducing agonistic activity of anti-HLA-A IgG antibody was significantly enhanced by conversion to a diabody format (Kimura et al., 2004; Sekimoto et al., 2006) . In particular, the (scFv) 2 format seems to be preferable, since a diabody contains a noncovalent association of two scFv molecules, which could cause instability by dissociation of the two scFvs from each other at a low concentration (Huang et al., 2005) . Although non-covalent diabody can be stabilized by engineering disulfide bonding between V H and V L (FitzGerald et al., 1997; Liu et al., 2009) , in particular case of the thrombopoietin receptor agonist antibody, (scFv) 2 format was preferable also because the agonist activity of (scFv) 2 form was significantly higher than that of the diabody form (Orita et al., 2005) .
The mouse VB22B thrombopoietin receptor agonist (scFv) 2 consists of identical VH1 and VH2 sequences, and identical VL1 and VL2 sequences connected by three 15-mer (G 4 S) 3 linkers (Huston et al., 1988; Orita et al., 2005) . Depending on the length of the linker, scFv can fold into monomeric scFv, dimeric scFv (diabody) or multimeric scFv (Desplancq et al., 1994) . Likewise, depending on the length of the three linkers, (scFv) 2 has the ability to fold into two different monomer forms: a bivalent scFv form, which results from the association of the adjacent VH1 and VL1, and adjacent VH2 and VL2, and a single-chain diabody form, which results from the head-to-tail association of VH1 and VL2, and VH2 and VL1 (Kipriyanov et al., 2003) . Mouse VB22B (scFv) 2 has been humanized to generate hVB22B (scFv) 2 with the same linker structure as the mouse version by CDR grafting onto to a human framework (unpublished results) .
For the first part of this work, we found that hVB22B (scFv) 2 is expressed as a mixture of two conformational isomers, the bivalent scFv form and the single-chain diabody form. We isolated two conformational isomers of hVB22B (scFv) 2 , and using the purified bivalent scFv and single-chain diabody forms of hVB22B (scFv) 2 , we showed that the thrombopoietin receptor agonist activity of the two conformational isomers is significantly different and only one of the conformational isomers is the active form. We revealed that these conformational isomers underwent novel isomerization in which the active form isomerized into the inactive form upon incubation at elevated temperatures. Although interconversion of scFv monomer to dimer or multimer is reported (Desplancq et al., 1994; Arndt et al., 1998) , to the best of our knowledge, isomerization of (scFv) 2 molecules has not been previously described. The effect of buffer conditions ( pH and NaCl concentration) on the rate of isomerization was studied and a mechanism of isomerization is proposed.
In order to promote the therapeutic development of a (scFv) 2 molecule with these conformational isomer and isomerization properties, it is necessary to purify the active form from the mixture of the two conformational isomers and stabilize the purified active form in the formulation so that isomerization into the inactive form is inhibited during storage. Therefore, for the second part of this work, we applied antibody engineering technology to overcome the issues we encountered. We introduced specific substitutions into the V H /V L interface of hVB22B (scFv) 2 to selectively express the desired form of conformational isomer. The effect of each substitution on the expression ratio of conformational isomers was studied. Furthermore, the effect of each substitution on the isomerization reaction, thrombopoietin receptor agonist activity and thermal stability was studied. These studies demonstrated that novel V H /V L interface engineering could overcome the above-mentioned issues involved in manufacturing hVB22B (scFv) 2 with thrombopoietin receptor agonist activity. Moreover, our results suggested that novel V H /V L interface engineering may be generally applicable to other (scFv) 2 molecules.
Materials and methods

Preparation of humanized VB22B (scFv) 2 TPO-like agonist antibody
Humanized VB22B (scFv) 2 (hVB22B (scFv) 2 ) was generated by humanization of mouse VB22B (unpublished results). hVB22B (scFv) 2 was expressed stably in CHO cells transfected with plasmids encoding VH1-(G 4 S) 3 -VL1-(G 4 S) 3 -VH2-(G 4 S) 3 -VL2. The amino acid sequences of VH1 and VH2 and of VL1 and VL2 were identical. Bulk hVB22B (scFv) 2 was obtained from culture supernatants by purification using epitope peptide affinity chromatography followed by gel filtration chromatography.
Isolation of two peaks in hVB22B (scFv) 2 by cation exchange chromatography Bulk hVB22B (scFv) 2 was injected into cation exchange chromatography using TSK-gel Bioassist S (4.6 mmw Â 50 mm column; Tosoh, Japan). Eluent A was 20 mM sodium phosphate buffer, pH 7.0, and eluent B was 20 mM sodium phosphate buffer, 500 mM NaCl, pH 7.0. The flow rate was 0.8 ml/min with 0% eluent B for 5 min after injection followed by linear gradient of 0 -30% eluent B for 25 min.
SDS-PAGE, size exclusion chromatography, mass spectrometry and peptide mapping analysis of hVB22B (scFv) 2 peaks 1 and 2
Purified hVB22B (scFv) 2 peak 1 and purified hVB22B (scFv) 2 peak 2 were isolated from bulk hVB22B (scFv) 2 using cation exchange chromatography. Peaks 1 and 2 were subjected to non-reduced SDS-PAGE analysis using 12% gel and size exclusion chromatography analysis using TSKgel Super2000 (Tosoh, Japan) with 50 mM sodium phosphate, 300 mM NaCl, pH 7.0, as a mobile phase at a flow rate of 0.2 ml/min.
Mass spectrometry analysis was performed to determine the molecular mass of peaks 1 and 2 using a Q-TOF mass spectrometer (Q Tof Ultima, Micro Mass). Sample solutions were introduced by infusion. Appended software (MassLynx, Micro Mass) was used for deconvolution of the obtained multivalent ion spectra.
Peptide mapping was performed to analyze the primary amino acid sequences of peaks 1 and 2. Peaks 1 and 2 were subjected to reduction and denaturation followed by carboxymethylation and trypsin digestion. Obtained peptide fragments were injected into reversed-phase chromatography using YMC-Pack-ODS (YMC, Japan). The obtained peptide maps for peaks 1 and 2 were compared.
Limited protease digestion analysis of hVB22B (scFv) 2 peaks 1 and 2 hVB22B (scFv) 2 peaks 1 and 2 were subjected to limited protease digestion. The digestion condition was carefully selected so that linker residues were selectively cleaved and no more than one linker was cleaved after the digestion. Limited protease digestion of peaks 1 and 2 was conducted at peak 1 or peak 2 with 0.1 mg/ml, subtilisin A (Calbiochem) 10 mg/ml, 378C for 30 min. Digestion products were subjected to reduced SDS-PAGE analysis using 12.5% PhastGel Homogeneous (GE Healthcare) and size exclusion chromatography analysis using TSKgel Super2000 (Tosoh, Japan) with DPBS(2) as a mobile phase and a flow rate of 0.2 ml/min.
Evaluation of thrombopoietin receptor agonist activity
Thrombopoietin receptor agonist activity was evaluated as previously described (Orita et al., 2005) . Specifically, thrombopoietin-dependent cell line, M-07e cells (Deutsche Sammlung von Mikroorganismen und Zellkulturen: DSMZ, Braunschweig, Germany), were washed twice with RPMI-1640/1% FBS medium and 5 Â 10 5 cells per well plated into 96-well tissue cultured plates containing 50 ml of RPMI1640/10% FBS medium, and then 50 ml of serially diluted samples were added. After being cultured for 48 h at 378C in 5% CO 2 , 10 ml of the cell count reagent, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) (Nacalai Tesque, Japan) was added, and further cultured for 4 h at 378C in 5% CO 2 . Absorbance at 450 and 655 nm was measured with Benchmark Plus (Bio-Rad).
Effect of pH and NaCl concentration on isomerization
Peaks 1 and 2 in 20 mM sodium citrate, 300 mM NaCl, pH 7.5 with antibody concentration at 2 mg/ml was prepared as a stock solution for isomerization study. The effects of pH and NaCl concentration on isomerization of hVB22B peak 1 (isomerization from bivalent scFv form to single-chain diabody form) and hVB22B peak 2 (isomerization from single-chain diabody form to bivalent scFv form) were investigated. Thirty different buffer solutions in 20 mM sodium citrate buffer were prepared at 10 different pH levels ( pH 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0 and 7.5 ) and at three different NaCl concentrations (0, 150 and 300 mM NaCl). Stock solutions were 20 times diluted with the buffers to obtain sample solutions. Sample solutions were incubated at 258C for 5 days, and then analyzed by cation exchange chromatography to evaluate the ratio of bivalent scFv forms to single-chain diabody forms.
Production of V H /V L interface-engineered hVB22B (scFv) 2 variants 1 and 2
To obtain V H /V L interface-engineered hVB22B (scFv) 2 , sitedirected mutagenesis of hVB22B (scFv) 2 was performed using the Stratagene QuikChange kit and confirmed by DNA sequencing. Glutamine at Kabat 39 in VH and Kabat 38 in VL were substituted to either glutamic acid or lysine. hVB22B (scFv) 2 variants 1 and 2 were expressed stably in CHO cells transfected with plasmid encoding
Q38K), respectively. Variants 1 and 2 were obtained from culture supernatants by purification using epitope peptide affinity chromatography followed by gel filtration chromatography.
Differential scanning calorimetric analysis
Differential scanning calorimetry (DSC) was conducted in 20 mM sodium citrate, 300 mM NaCl, pH 7.5, with antibody concentration at 0.5 mg/ml. N-DSC (Microcal) was used and the scanning temperature was elevated from 208C to 1008C at a rate of 18C/min. Using an attached computer program, the melting temperatures of peaks 1 and 2 were obtained.
Isomerization study of hVB22B (scFv) 2 peaks 1 and 2 and V H /V L interface-engineered hVB22B (scFv) 2 variants 1 and 2
Samples with an antibody concentration of 0.1 mg/ml in 20 mM sodium citrate, pH 6.0, were incubated at 408C and analyzed on days 0, 6 and 12 by cation exchange chromatography to determine the ratio of bivalent scFv forms to single-chain diabody forms.
Results
Characterization of hVB22B (scFv) 2 conformational isomers and their novel bidirectional isomerization
Isolation of two peaks in hVB22B (scFv) 2 by cation exchange chromatography. The chromatographic condition for separating the hVB22B (scFv) 2 conformational isomers was determined and cation exchange chromatography by TSK-gel Bioassist S was used to separate hVB22B (scFv) 2 into two peaks (data not shown), in which the acidic peak (eluted first) was named peak 1 and the basic peak (eluted later) was named peak 2. Both peaks were purified for further analysis.
SDS-PAGE, size exclusion chromatography, mass spectrometry and peptide mapping analysis of hVB22B (scFv) 2 peaks 1 and 2. Non-reduced SDS-PAGE and reduced SDS-PAGE analyses of peaks 1 and 2 showed that both peaks 1 and 2 were single bands with identical mobility, and size exclusion chromatography analysis showed no difference in elution time (data not shown). TOF-MS analysis revealed that peak 1 had a molecular mass of 53 768 Da, and peak 2 had a molecular mass of 53 769 Da. No significant difference was observed in the peptide mapping analysis of peaks 1 and 2 (data not shown). These results revealed that peaks 1 and 2 in hVB22B (scFv) 2 have identical primary structures with different retention times in cation exchange chromatography, suggesting that peaks 1 and 2 are conformational isomers.
Limited protease digestion analysis of hVB22B (scFv) 2 peaks 1 and 2. Schematic representatives of the primary structure of hVB22B (scFv) 2 and two conformational isomers of (scFv) 2 are shown ( Fig. 1A and B) . Association between adjacent VH1 and VL1 and adjacent VH2 and VL2 results in the formation of a bivalent scFv form with two scFvs on both the N and C terminals, whereas head-to-tail association of VH1 with VL2 and of VH2 with VL1 results in the formation of a diabody-like structured single-chain fragment, single-chain diabody form. The linker portion of a singlechain antibody is flexible rather than structurally defined, and thus susceptible to protease digestion and can be specifically cleaved by optimizing the digestion conditions. If the conditions of hVB22B (scFv) 2 are carefully selected so that no more than one linker is cleaved, the digestion products of the two conformational isomers should be different due to their different patterns of V H /V L association ( Fig. 2A ). In the case of a bivalent scFv form, when one of the edge linkers is cleaved, the molecular size of the (scFv) 2 would not change because of its non-covalent association of V H and V L ; however, when the middle linker is cleaved, the (scFv) 2 Fig. 1 . Schematic representatives of hVB22B (scFv) 2 primary structure (A) and two forms of conformational isomer (B). The amino acid sequences of VH1 and VH2 and of VL1 and VL2 are identical.
Novel V H /V L interface engineering of single-chain diabody would be divided into two half-size molecules, an Fv of VH1 and VL1 and an Fv of VH2 and VL2. On the other hand, in the case of a single-chain diabody form, cleavage of any one of the three linkers would not significantly change the molecular size of the (scFv) 2 because of the non-covalent head-to-tail association of V H and V L . The difference in the digestion products can be analyzed by size exclusion chromatography. Purified peak 1 of hVB22B (scFv) 2 and purified peak 2 of hVB22B (scFv) 2 were subjected to limited protease digestion. SDS-PAGE analysis of the digestion products of peaks 1 and 2 exhibited comparable amounts of cleavage product (data not shown). On the other hand, size exclusion chromatography analysis of the digestion products of peaks 1 and 2 demonstrated that half-size molecules were clearly observed in the digestion product of peak 1 but not in the digestion product of peak 2 (Fig. 2B) . Thus, hVB22B (scFv) 2 peak 1 was identified as a bivalent scFv form and peak 2 was identified as a single-chain diabody form.
Thrombopoietin receptor agonist activity of the bivalent scFv and the single-chain diabody forms. Thrombopoietin receptor agonist activity of the purified hVB22B (scFv) 2 bivalent scFv form ( peak 1) and single-chain diabody form ( peak 2) was evaluated using the thrombopoietin-dependent cell line M-07e. hVB22B (scFv) 2 peak 2 exhibited strong thrombopoietin receptor agonistic activity, whereas hVB22B (scFv) 2 peak 1 showed approximately 100-fold lower activity than peak 2 (Fig. 2C) .
Bidirectional isomerization between the bivalent scFv and single-chain diabody forms. Purified hVB22B (scFv) 2 peak 1 and purified peak 2 were incubated in 20 mM sodium citrate, pH 6.0 at 408C for 6 days. Before and after incubation, samples were analyzed by cation exchange chromatography. Incubation of purified peak 1 resulted in a significant decrease in peak 1 and increase in peak 2 (Fig. 3A) , and incubation of purified peak 2 resulted in a decrease in peak 2 and increase in peak 1 (Fig. 3B) . The thrombopoietin receptor agonist activity of purified peak 1 significantly increased after incubation and resulted in activity comparable to that of peak 2, whereas the thrombopoietin receptor agonist activity of purified peak 2 before and after incubation did not show a significant change (data not shown). These results demonstrate that the two conformational isomers are under equilibrium and thereby the bivalent scFv form can transform into a single-chain diabody form, and the single-chain diabody form can transform into a bivalent scFv form by incubation at elevated temperatures. We termed this novel bidirectional transformation between two conformational isomers 'isomerization'.
Effect of pH and NaCl concentration on isomerization. Purified hVB22B (scFv) 2 peaks 1 and 2 were incubated under various conditions (0 -300 mM NaCl and pH 3.5-7.5) to obtain an isomerization profile and elucidate the isomerization mechanism. Isomerization from bivalent scFv form to single-chain diabody form ( peak 1 to peak 2) and isomerization from single-chain diabody form to bivalent scFv form ( peak 2 to peak 1) were both accelerated at lower pH and lower NaCl concentrations, especially below pH 6.0 and at 0 mM NaCl (data not shown). Isomerization from peak 1 to peak 2 was more rapid than isomerization from peak 2 to peak 1 in the same buffer conditions. Isomerization of peak 2, the active form of hVB22B (scFv) 2 , into inactive peak 1 occurred even under the most stable condition (i.e. 300 mM NaCl, pH 7.5).
Design, expression and characterization of V H /V L interface-engineered hVB22B (scFv) 2
Design of V H /V L interface-engineered hVB22B (scFv) 2 variant 1 and hVB22B (scFv) 2 variant 2. Pharmaceutical development of (scFv) 2 molecules, such as hVB22B (scFv) 2 with conformational isomers and isomerization properties, requires separation of the purified single-chain diabody form from the mixture of the two conformational isomers and inhibition of isomerization into an inactive bivalent scFv form during storage. In order to overcome these difficulties, we explored a novel approach to control the association of V H and V L to selectively express desired conformational isomers.
The association of V H and V L results in the formation of a stable V H /V L interface. Residues located in the V H /V L interface are strictly conserved in the sequence in the antibody variable region (Chatellier et al., 1996; Vargas-Madrazo et al., 2003) . The conserved V H /V L interface is mainly composed of hydrophobic interactions between H37, H45, H47, H89, H91 and H104 in heavy chain framework residues and L36, L44, L46, L85, L87 and L98 in light chain framework residues, and of hydrogen bonding between H39 and L38. A model structure of the hVB22B (scFv) 2 was generated by MOE (Chemical Computation Group) using a general homology modeling method (Morea et al., 2000) . We focused on the hydrogen bonding between glutamine at H39 and glutamine at L38 (Fig. 4A and 4B) . The hydrogen-bonding interaction between H39 and L38 was replaced with an electrostatic attraction (Fig. 4C ) and repulsion to enhance the desired V H / V L association and inhibit the undesired V H /V L association. In order to preferably fold into a bivalent scFv form, H39 in VH1 and L38 in VL2 were substituted with glutamic acid and H39 in VH2 and L38 in VL1 were substituted with lysine (referred to as hVB22B (scFv) 2 variant 1), thereby enhancing the association of VH1/VL1 and VH2/VL2 by electrostatic attraction between the glutamic acid and lysine, and inhibiting the association of VH1/VL2 and VH2/VL1 by electrostatic repulsion. Likewise, in order to preferably fold into a singlechain diabody form, H39 in VH1 and L38 in VL1 were both substituted with glutamic acid and H39 in VH2 and L38 in VL2 were both substituted with lysine (referred to as hVB22B (scFv) 2 variant 2). Schematic representatives of the primary structures of hVB22B (scFv) 2 wild type and hVB22B (scFv) 2 variants 1 and 2 are shown (Fig. 4D) . . Bidirectional isomerization of purified hVB22B (scFv) 2 peak 1 (bivalent scFv form) and peak 2 (single-chain diabody form). Cation exchange chromatography analysis of peak 1 (A) and peak 2 (B) before (upper chromatogram) and after (lower chromatogram) incubation at 408C for 6 days.
Novel V H /V L interface engineering of single-chain diabody Expression and analysis of conformational isomers of V H /V L interface-engineered variants 1 and 2. hVB22B (scFv) 2 wild type and hVB22B (scFv) 2 variants 1 and 2 were purified by affinity-tag chromatography followed by gel filtration chromatography from the culture medium of each stable CHO cell line. No differences were observed in the expression levels among wild type, variants 1 and 2. In the gel filtration chromatography step, three of the (scFv) 2 molecules exhibited different monomer to multimer ratios. The percentage of monomer for wild type was 59%, whereas values for variants 1 and 2 were 77 and 89%, respectively, demonstrating that these substitutions improved the monomer to multimer ratio of the secreted product and therefore the monomer recovery after purification. Monomer fractions were collected as purified products of hVB22B (scFv) 2 wild type, variants 1 and 2.
hVB22B (scFv) 2 wild type and V H /V L interfaceengineered variants 1 and 2 were subjected to cation exchange chromatography for analysis of the conformational isomers (Fig. 5A) . Variant 1 eluted as a single peak with the same retention time as peak 1 of hVB22B (scFv) 2 wild type, suggesting that variant 1 was dominantly secreted as bivalent scFv form. Likewise, variant 2 eluted as a single peak with the same retention time as peak 2 of hVB22B (scFv) 2 wild type, suggesting that variant 2 was dominantly secreted as single-chain diabody form. Consistent with cation exchange chromatography analysis, native gel isoelectric focusing of the samples showed that the mobility of peak 1 and variant 1 was identical, and the mobility of peak 2 and variant 2 was identical (data not shown). In order to confirm the results of the cation exchange chromatography analysis, purified peaks 1 and 2 of hVB22B (scFv) 2 , and variants 1 and 2 of V H /V L interface-engineered hVB22B (scFv) 2 were subjected to limited protease digestion analysis. Size exclusion chromatography analysis of the digestion products showed that half- size molecules (a digestion product specific to bivalent scFv form) were observed only in peak 1 and variant 1, but not in peak 2 and variant 2 (Figs 2B and 5B) .
These results clearly demonstrate that variants 1 and 2 were dominantly expressed as a bivalent scFv form and a single-chain diabody form, respectively. Despite the fact that hVB22B (scFv) 2 wild type was expressed as a mixture of the two conformational isomers (24% bivalent scFv form and 76% single-chain diabody form), substitution of the hydrogen bonding interaction between H39 and L38 with electrostatic attraction and repulsion completely inhibited the expression of the undesired conformational isomer.
Thrombopoietin receptor agonistic activity of V H /V L interface-engineered variants 1 and 2. Residues in the V H / V L interface are important for the antigen-binding capability of an antibody (Chatellier et al., 1996) , and so the effect of substitutions introduced in variants 1 and 2 on thrombopoietin receptor agonist activity were evaluated (Fig. 5C ). Thrombopoietin receptor agonist activity of the purified peaks 1 and 2 of hVB22B (scFv) 2 and variants 1 and 2 of V H /V L interface-engineered hVB22B (scFv) 2 were assessed using M-07e. Both hVB22B (scFv) 2 peak 2 and variant 2 single-chain diabody forms exhibited strong and comparable thrombopoietin receptor agonist activity, suggesting that substitutions in H39 and L38 did not alter the antigen-binding characteristic. hVB22B (scFv) 2 peak 1 and variant 1 bivalent scFv forms had approximately 100 to 1000-fold lower activity than hVB22B (scFv) 2 peak 2 and variant 2 single-chain diabody forms. Slightly higher activity was observed for hVB22B (scFv) 2 peak 1 compared to variant 1.
Thermal stability and isomerization study of V H /V L interface-engineered variants 1 and 2. Residues in the V H / V L interface are also important for the stability of an antibody (Tan et al., 1998; Wörn A et al., 1998; Jäger et al., 1999) , and so the effect of substitution on thermal stability was assessed by measuring the melting temperature using DSC. The melting temperatures of purified peaks 1 and 2 of hVB22B (scFv) 2 , and variants 1 and 2 of V H /V L interface-engineered hVB22B (scFv) 2 were comparable, suggesting that substitutions in H39 and L38 did not destabilize the molecule (Table I) . Both in wild type and V H /V L interface-engineered hVB22B (scFv) 2 , the melting temperature of the single-chain diabody form was slightly higher than that of the bivalent scFv form.
Purified peaks 1 and 2 of hVB22B (scFv) 2 , and variants 1 and 2 of V H /V L interface-engineered hVB22B (scFv) 2 were evaluated for the effects on the isomerization of making specific substitutions in the V H /V L interface to selectively express conformational isomers. Purified peaks 1 and 2 of hVB22B (scFv) 2 , and variants 1 and 2 of V H /V L interface-engineered hVB22B (scFv) 2 were incubated at 408C for 6 and 12 days, respectively, and the isomerization reactions analyzed by cation exchange chromatography to determine the time course of the conformational isomer ratio (Fig. 6 ). Approximately 10% of hVB22B (scFv) 2 peak 2 isomerized to peak 1 after incubation, whereas single-chain diabody form variant 2 did not isomerize to the bivalent scFv form. Similarly, approximately 90% of hVB22B (scFv) 2 peak 1 isomerized to peak 2 after incubation, whereas bivalent scFv variant 1 did not isomerize to singlechain diabody form. The results demonstrate that both variants 1 and 2 of V H /V L interface-engineered hVB22B (scFv) 2 were resistant to isomerization.
Discussion
Two conformational isomers in hVB22B (scFv) 2 were successfully separated by cation exchange chromatography, and Novel V H /V L interface engineering of single-chain diabody the forms of peaks 1 and 2 were identified by biochemical analysis and limited protease digestion as bivalent scFv form and single-chain diabody form, respectively. Stable noncovalent association of V H and V L was important factor for successful identification of conformational isomers by the limited protease digestion. On the other hand, it was reported that non-covalent association of V H and V L in diabody format dissociated at low antibody concentration (Huang et al., 2005) . This discrepancy could be explained by the fact that the limited protease digestion reaction in this study was conducted at relatively high antibody concentration, and the relatively high stability of V H /V L interface suggested by high-melting temperature of hVB22B (scFv) 2 (Table I) . The thrombopoietin receptor agonist activity of the single-chain diabody form was significantly higher than that of the bivalent scFv form. Because purified peak 1 contained a small amount of peak 2 ( possibly due to isomerization during storage) and isomerization of peak 1 into peak 2 could have occurred during the incubation period of the thrombopoietin receptor agonist activity assay, the thrombopoietin receptor agonist activity of pure peak 1 should have been much less than was observed ( Fig. 2C and Fig. 5C ). Therefore, we can conclude that the single-chain diabody form is an active form of this humanized thrombopoietin receptor agonist (scFv) 2 antibody and the bivalent scFv form is a substantially inactive form. Considering the therapeutic application of (scFv) 2 molecule, proteolytic stability of the molecule is important. Since two conformational isomers did not exhibit significant difference in sensitivity to the protease linker digestion, stability of the two conformational isomers in plasma is expected to be comparable. Using the purified bivalent scFv form and the single-chain diabody form of hVB22B (scFv) 2 , we demonstrated that these two conformational isomers are under equilibrium, and surprisingly, single-chain diabody form can transform into bivalent scFv form, and bivalent scFv form can transform into single-chain diabody form upon incubation at an elevated temperature. Although a significant number of (scFv) 2 molecules have been reported to date, bidirectional isomerization between two conformational isomers of (scFv) 2 has not been previously described, possibly due to a previous lack of methods for identifying conformational isomers (i.e. limited protease digestion) and for quantitative analysis of two conformational isomers (i.e. cation chromatography analysis). Previously, it was reported that monomer -dimer transition of scFv occurs via an open monomer, an intermediate structure in the transition state in which V H /V L association is absent (Arndt et al., 1998) . Monomer (scFv) 2 is also reported to dimerize into a tandem diabody via an open monomer (Kipriyanov et al., 2003) . We propose that (scFv) 2 isomerization occurs via dissociation of the former V H /V L interface and formation of a new V H /V L interface via the open monomer (Fig. 7A ). In the case of (scFv) 2 isomerization, two V H /V L (VH1/VL1 and VH2/VL2) associations on both sides of the bivalent scFv form dissociate into open monomer intermediates, and then by intramolecular domain swapping, form new V H /V L (VH1/VL2 and VH2/VL1) that result in isomerization into single-chain diabody form. This proposed mechanism of isomerization suggests that the packing stability of the V H /V L interface is important in controlling isomerization. Isomerization studies at 258C in various buffer conditions showed that isomerization was accelerated at lower pH levels and lower NaCl concentrations. The V H /V L interface is composed of a hydrophobic interface and single hydrogen bonding between Kabat VH39 and Kabat VL38 (Tan et al., 1998) . Since the hydrophobic interaction is dependent on ionic strength and weakens as ionic strength weakens, the V H /V L interface is destabilized by low ionic strength media and thus isomerization is accelerated at low concentrations of NaCl. Accelerated isomerization at pH less than 6.0 indicates decreased stability of the V H /V L interface at pH ,6.0. This may be due to decreased V H /V L interactions at a pH less than 6.0. Previous studies have reported that monomer -dimer transition of scFv molecules via an open monomer is dependent on the solution conditions, such as pH and ionic strength, and that these transitions are accelerated by lower pH and low ionic strength, suggesting that the stability of the V H /V L interface of scFv also decreases under conditions of low ionic strength and low pH (Arndt et al., 1998) and supporting the theory that the mechanism of (scFv) 2 isomerization is via open monomers. In this study, isomerization at 258C from the bivalent scFv form to the single-chain diabody form was faster than from a single-chain diabody form to bivalent scFv form. To explain the results, we conducted a stability study of the two conformational isomers by differential scanning calorimetric analysis (Table I ) and guanidine hydrochloride denaturing analysis (data not shown), and found that the single-chain diabody form was slightly more thermodynamically favorable than the bivalent scFv form. This small difference in thermal stability may be derived from the additional stabilizing interaction between the two Fvs in a single-chain diabody form and/or by destabilization from the association of adjacent V H and V L with a linker of 15 amino acid residues, which may not be long enough, in the bivalent scFv form. Formation of the preferred single-chain diabody form in hVB22B (scFv) 2 when expressed in mammalian cells (24% bivalent scFv form and 76% single-chain diabody form) (Fig. 6A ) is assumed to be also due to this slight difference in thermal stability between the two forms.
One of the differences between previously described monomer -dimer transitions of scFv (Lee et al., 2002) and the novel isomerization of (scFv) 2 described herein is that monomer -dimer transition is an intermolecular reaction and thus dependent on antibody concentration. The isomerization that we demonstrated is an intramolecular reaction and thus concentration independent. In order to develop (scFv) 2 molecules, such as hVB22B (scFv) 2 , as a therapeutic antibody, the active form needs to be purified and remain stable in the formulation. In the case of hVB22B (scFv) 2 , the single-chain diabody form was found to be an active form, but in a different (scFv) 2 molecule, such as a BiTE molecule for retargeting T-cells to tumor cells (Baeuerle et al., 2009) , the bivalent scFv form could be an active form. From the fact that singlechain diabody form of hVB22B (scFv) 2 exhibited stronger agonistic activity toward thrombopoietin receptor homodimer than bivalent scFv form, it was suggested that two antigen binding sites of single-chain diabody form is spatially closer than bivalent scFv form. Therefore, single-chain diabody form could be a better form for cross-linking two receptors on the surface of the same cell. On the other hand, since two antigen binding sites of single-chain diabody form could be spatially too close to each other for cross-linking two receptors from the different cells (such as BiTE molecule), bivalent scFv form could be a better form for such application. In both case, stable storage of an active form requires inhibition of the isomerization to the inactive form. Although scFv dimerization could be controlled by lowering the antibody concentration and optimizing the buffer condition of the formulation, suppression of intramolecular (scFv) 2 isomerization is only controlled by optimizing the buffer conditions of the formulation. Even in the most stable condition tested (300 mM NaCl, pH 7.5), isomerization of hVB22B (scFv) 2 was not completely inhibited. These results highlight the significant difficulty in developing a formulation of hVB22B (scFv) 2 or other (scFv) 2 molecules, such as bispecific antibody format for recruiting effector cells to tumor cells (Baeuerle et al., 2009) , as a therapeutic antibody. Furthermore, separation of the purified active form from the mixture of two conformational isomers in large scale production might also pose a difficulty in manufacturing.
In order to overcome these difficulties in the pharmaceutical development of (scFv) 2 molecules, we explored a recombinant approach to control the association of V H and V L and express the desired conformational isomers. Previously, it was reported that (scFv) 2 with a linker consisting of VH-linker (5-mer)-VL-linker (15-mer)-VH-linker (5-mer)-VL (represented by 5-15-5) is believed to predominantly fold into a single-chain diabody form, whereas (scFv) 2 with a 15-5-15 linker is believed to predominantly fold into a bivalent diabody form (Meng et al., 2004) . However, confirmation study of the forms (e.g. limited protease digestion) was not performed in that study. A study using mouse VB22B (scFv) 2 has shown that the thrombopoietin receptor agonist activity of mouse VB22B (scFv) 2 with a 5-15-5 linker, which is believed to predominantly fold into single-chain diabody form, was significantly weaker than that of mouse VB22B (scFv) 2 with a 15-15-15 linker, possibly due to a small difference in the tertiary structure derived from linker length (unpublished results). Therefore, we explored an alternative approach to control the association of V H and V L for the selective expression of desired conformational isomers. Novel substitutions within the V H /V L interface of (scFv) 2 , in which hydrogen bonding interaction between H39 and L38 was substituted with electrostatic attraction and repulsion promoting the formation of a specific conformational isomer, were shown to be significantly effective for selective expression of the respective conformational isomers in variants 1 and 2. According to our data, simultaneous introduction of both electrostatic attraction and repulsion to V H /V L interfaces such as VH1(E)-VL1(E)-VH2(K)-VL2(K)) was more effective than electrostatic repulsion to a single V H /V L interface such as
(data not shown). Novel V H /V L interface engineering of single-chain diabody Furthermore, both variants 1 and 2 exhibited higher monomer recovery than wild type. Dimer and multimer (scFv) 2 molecules are thought to result from the intermolecular association of V H and V L (Kipriyanov et al., 1999; Le Gall et al., 2004) . Introducing substitutions in variants 1 and 2 inhibited the interaction of V H and V L that have the same charge, thereby decreasing the chance of intermolecular association and improving monomer to multimer ratio of secreted molecule. Importantly, thrombopoietin receptor agonist activity and the melting temperatures of variant 2 were comparable to that of purified hVB22B (scFv) 2 peak 2, demonstrating that these substitutions have a minimal effect on the antibody structure. These results are in sharp contrast to previously reported knobs-into-hole substitutions, in which heterodimerization of a diabody to enhance bispecific diabody formation was achieved by remodeling the hydrophobic interaction of V H /V L interface residues (Zhu et al., 1997) . Zhu et al. reported using knobs-into-hole substitution to selectively produce a bispecific diabody that targets HER2 and CD3. In their best variant, with Y87A/F98M substitutions in anti-HER2 V L and V37F/L45W substitutions in anti-HER2 V H , desired V H /V L pairing reached 92%, although the binding to HER2 and expression level were significantly decreased compared with the parent diabody. In the case of variants 1 and 2 in our study, the desired V H /V L pairing reached 100% and the agonist activity, expression level and stability were maintained. The superiority of our novel V H /V L interface substitutions compared with knobs-into-hole substitutions by Zhu et al. could be explained as follows. First, the hydrogen bonding between the H39 and L38 substituted in variants 1 and 2 is located at the bottom of the V H /V L interface, which is far from the antigen-binding site, whereas the hydrophobic core mutated by Zhu et al. is located at the middle of the V H /V L interface, close to the antigen-binding site. Second, concerning the packing geometry of the V H /V L , the effect in variants 1 and 2 of substituting a Gln-Gln hydrogen bonding with a Glu-Lys electrostatic interaction, would be minimal ( Fig. 4B and C) , whereas remodeling the hydrophobic core by the knobs-into-hole format may have a more profound effect. Hydrogen bonding between H39(Gln) and L38(Gln) is highly conserved among natural human V H and V L interactions. Surrounding residues of H39(Gln) and L38(Gln) in V H /V L interface of hVB22B are H45(Leu), H89(Val), H91(Tyr), L44(Pro), L85(Val) and L87(Tyr) (Fig. 4B) , and these residues are also well conserved among natural human V H and V L sequences. Therefore, this novel approach of V H /V L interface engineering is expected to be generally applicable to various human and humanized (scFv) 2 molecules for selective expression of desired conformational isomers.
In addition to the expression of the desired conformational isomer, both variants 1 and 2 were resistant to isomerization upon incubation at elevated temperatures. Parent hVB22B (scFv) 2 wild type is suggested to be under equilibrium between two conformational isomers with open monomer as a transition state. Since the melting temperature of variant 2 is comparable to parent hVB22B (scFv) 2 peak 2, we can assume that the equilibrium constant between parent hVB22B (scFv) 2 peak 2 and its open monomer is comparable to the equilibrium constant between variant 2 and its open monomer. Therefore, the mechanism we propose to explain the complete isomerization resistance of variant 2 is not that it inhibits the dissociation of V H /V L into open monomer, but that it inhibits the re-association of V H /V L into bivalent scFv form. Parent hVB22B (scFv) 2 open monomer can fold into both conformational isomers (Fig. 7A) , whereas the variant 2 open monomer without exception folds back to a single-chain diabody form due to the strong electrostatic repulsion in the V H /V L interface of the bivalent scFv form, and, vice versa, variant 1 open monomer folds back without exception to the bivalent scFv form (Fig. 7B) . Although modification of H39 and L38 has been reported on its effect on stability and refolding efficiency of scFv (Tan et al., 1998) and V L homodimer association (Raffen et al., 1998) , this is the first study on its effect on expression of (scFv) 2 conformational isomer, (scFv) 2 isomerization, biological activity and stability.
These results demonstrate that novel V H /V L interface engineering of (scFv) 2 molecules enabled not only expression of selective conformational isomers but also stable storage of the desired conformational isomer without loss of antigen-binding capability or thermal stability. Therefore, this novel V H /V L interface engineering should facilitate the therapeutic development of hVB22B (scFv) 2 .
Conclusions
Two conformational isomers, a single-chain diabody form and bivalent scFv form, of hVB22B (scFv) 2 , showed significantly different thrombopoietin receptor agonist activity and were found to exhibit novel bidirectional isomerization. V H / V L interface engineering of (scFv) 2 molecules, in which the hydrogen bonding between H39 and L38 was substituted with electrostatic attraction and repulsion to enhance the desired V H /V L association and inhibit the undesired V H /V L association, has enabled expression of selective conformational isomers without loss of thrombopoietin receptor agonist activity or thermal stability. Moreover V H /V L interface-engineered (scFv) 2 was completely resistant to isomerization, enabling stable storage of the desired conformational isomer. Therefore, this novel V H /V L interface engineering would facilitate the therapeutic development of hVB22B (scFv) 2 . The hydrogen bonding between H39 and L38 and the surrounding residues are highly conserved in human antibody sequences, and thus this V H /V L interface engineering could be applied to various (scFv) 2 molecules to selectively express desired conformational isomers and inhibit isomerization.
